Skip to main content

pramlintide acetate 1000 ug/mL Medicare Part D Coverage

Brand name: SymlinPen
Dosage form
INJECTION
Route
SUBCUTANEOUS
36%
of Medicare Part D plans
cover pramlintide acetate
1,970 of 5,530 plans
4.9
Avg. formulary tier
$86.00
Median 30-day copay
$84.00–$88.00
Copay range

Formulary Tier Distribution

How Medicare Part D plans classify pramlintide acetate. Lower tiers = lower copays.

Tier 1 - Preferred Generic 2%
41 plans • avg $0.00/mo
Tier 2 - Generic 0%
2 plans • avg $0.00/mo
Tier 3 - Preferred Brand 1%
26 plans • avg $5.06/mo
Tier 4 - Non-Preferred Drug 2%
39 plans • avg $0.00/mo
Tier 5 - Specialty 93%
1,832 plans • avg $0.00/mo
Tier 6 - Select Care 2%
30 plans • avg $0.00/mo

Find the cheapest plan for pramlintide acetate

Enter your ZIP code to compare every plan in your area side-by-side.

Compare Plans for pramlintide acetate →

Get pramlintide acetate Delivered to Your Door

Compare prices and get discounts from trusted online pharmacies

DrugCovered may earn commissions from pharmacy purchases. Prices and availability vary. Always consult your doctor before starting or changing medications.

pramlintide acetate Medicare Coverage by State

Coverage rates and average costs vary significantly by state. Click a state to see the specific plans available there.

Frequently Asked Questions about pramlintide acetate

36% of Medicare Part D plans cover pramlintide acetate. It is most commonly placed on Tier 5. Coverage varies by plan and geographic area.

The median 30-day copay for pramlintide acetate on Medicare Part D is $86.00 at a preferred pharmacy. Costs range from $84.00 to $88.00 depending on the plan.

pramlintide acetate is placed on Tier 5 by most Medicare Part D plans. Lower tier numbers generally mean lower copays.

0% of plans require prior authorization for pramlintide acetate. Prior authorization means your doctor must confirm the drug is medically necessary before the plan will cover it.

Coverage statistics based on CMS formulary data for plan year 2026. Data updated regularly. Methodology →